scholarly journals The Use of Tissue Plasminogen Activator as Continuous Infusion into an Arteriovenous Hemodialysis Access in the Hemodialysis Unit: A Case Series

2015 ◽  
Vol 2 ◽  
pp. 35 ◽  
Author(s):  
Elene van der Merwe ◽  
Rick Luscombe ◽  
Mercedeh Kiaii
Keyword(s):  
Continuous Infusion ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Case Series ◽  
Hemodialysis Access ◽  
Hemodialysis Unit ◽  
Tissue Plasminogen

Distant haemorrhagic effects in intra-arterial Tissue Plasminogen Activator The effect of a bolus dose

1994 ◽  
Vol 80 (2) ◽  
pp. 66-70
Author(s):  
N P J Cripps ◽  
A S Ward
Keyword(s):  
Continuous Infusion ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Bolus Dose ◽  
Entry Site ◽  
Arterial Tissue ◽  
Tissue Plasminogen ◽  
Peripheral Arterial ◽  
Haemorrhage Rate ◽  
Arterial Thrombolysis

AbstractDetails are reported of four patients who developed serious distant haemorrhagic complications while undergoing peripheral arterial thrombolysis with intra-arterial tissue plasminogen activator (t-PA). The thrombolytic regime comprised a 20 mg bolus of t-PA followed by a continuous infusion of 1 mg/hr. Four additional cases of haemorrhage at the catheter entry site were also encountered in a group of 23 patients exposed to the bolus-infusion t-PA regimen. The high haemorrhage rate (31 % ) is a significant disadvantage of this thrombolytic protocol.

scholarly journals Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Małgorzata Dybowska ◽  
Monika Szturmowicz ◽  
Lucyna Opoka ◽  
Piotr Rudziński ◽  
Witold Tomkowski
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Case Series ◽  
Recombinant Tissue Plasminogen Activator ◽  
Purulent Pericarditis ◽  
Tissue Plasminogen

Efficacy and safety of recombinant tissue plasminogen activator for venous thrombosis after paediatric heart surgery

2017 ◽  
Vol 28 (2) ◽  
pp. 214-221 ◽  
Author(s):  
Lindsey B. Justice ◽  
David P. Nelson ◽  
Joseph Palumbo ◽  
Jaclyn Sawyer ◽  
Manish N. Patel ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Venous Thrombosis ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Heart Surgery ◽  
Case Series ◽  
Recombinant Tissue Plasminogen Activator ◽  
High Risk Population ◽  
Young Infants ◽  
Tissue Plasminogen

AbstractObjectiveReports in the literature of treatment with recombinant tissue plasminogen activator following cardiac surgery are limited. We reviewed our experience to provide a case series of the therapeutic use of tissue plasminogen activator for the treatment of venous thrombosis in children after cardiac surgery. The data describe the morbidity, mortality, and clinical outcomes of tissue plasminogen activator administration for treatment of venous thrombosis in children following cardiac surgery.DesignThe study was designed as a retrospective case series.SettingThe study was carried out in a 25-bed cardiac intensive care unit in an academic, free-standing paediatric hospital.PatientsAll children who received tissue plasminogen activator for venous thrombosis within 60 days of cardiac surgery, a total of 13 patients, were included.InterventionsData was collected, collated, and analysed as a part of the interventions of this study.Measurements and main resultsPatients treated with tissue plasminogen activator were principally young infants (median 0.2, IQR 0.07–0.58 years) who had recently (22, IQR 12.5–27.3 days) undergone cardiac surgery. Hospital mortality was high in this patient group (38%), but there was no mortality attributable to tissue plasminogen activator administration, occurring within <72 hours. There was one major haemorrhagic complication that may be attributable to tissue plasminogen activator. Complete or partial resolution of venous thrombosis was confirmed using imaging in 10 of 13 patients (77%), and tissue plasminogen activator administration was associated with resolution of chylous drainage, with no drainage through chest tubes, at 10 days after tissue plasminogen activator treatment in seven of nine patients who had upper-compartment venous thrombosis-associated chylothorax.ConclusionsOn the basis of our experience with administration of tissue plasminogen activator in children after cardiac surgery, tissue plasminogen activator is both safe and effective for resolution of venous thrombosis in this high-risk population.

scholarly journals Use of recombinant tissue plasminogen activator for treatment of recalcitrant anterior uveitis: A case series

2018 ◽  
Vol 13 (5) ◽  
pp. 483-487 ◽  
Author(s):  
Sylves Patrick ◽  
Chan Hui-Tze ◽  
Wan Hitam Wan-Hazabbah ◽  
Embong Zunaina ◽  
Yaakub Azhany ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Anterior Uveitis ◽  
Case Series ◽  
Recombinant Tissue Plasminogen Activator ◽  
Tissue Plasminogen

scholarly journals Management of acute submacular hemorrhage using intravitreal injection of tissue plasminogen activator and gas: A case series

2020 ◽  
Vol 8 ◽  
pp. 2050313X2097033
Author(s):  
Athanasios Karamitsos ◽  
Vasileios Papastavrou ◽  
Tsveta Ivanova ◽  
David Cottrell ◽  
Kevin Stannard ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Visual Acuity ◽  
Growth Factor ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Case Series ◽  
Recombinant Tissue Plasminogen Activator ◽  
Vascular Endothelial ◽  
Tissue Plasminogen ◽  
Endothelial Growth Factor

The objective of this case series is the evaluation of the efficacy and visual outcomes after displacement of subretinal hemorrhage using intravitreal injection of recombinant tissue plasminogen activator, expansile gas, and in some cases an anti-vascular endothelial growth factor agent. A case series of 28 eyes of 28 patients (16 men and 12 women with age range 67–95 years) suffering from subretinal hemorrhage (duration range 1–15 days) caused by age-related macular degeneration or retinal macroaneurysm is presented. All the patients were treated with intravitreal injection of recombinant tissue plasminogen activator and gas and some of them received an anti-vascular endothelial growth factor agent between January 2013 and December 2016. The outcomes assessed were visual acuity (preoperatively 1 week, and 1 month postoperatively) with respect to duration and dimension of hemorrhage, displacement of hemorrhage, and possible complications of the procedure. Successful displacement of hemorrhage was achieved in 25 patients (89.3%), 18 of 28 patients had significant improvement in visual acuity 1 week after the treatment, and 22 of 28 patients had significant improvement in visual acuity 1 month after the treatment. The mean improvement of all patients with anatomical displacement of the hemorrhage in visual acuity was 0.7 ± 0.5 (LogMAR) in 1 month. Two patients developed vitreous hemorrhage after the procedure and one retinal detachment. Visual outcome a month after therapy displayed week correlation with duration, diameter, and thickness of hemorrhage. The results lead to the conclusion that intravitreal treatment of recombinant tissue plasminogen activator and expansible gas with or without injection of anti-vascular endothelial growth factor agent is effective in improving visual acuity and displacing submacular hemorrhage secondary to age-related macular degeneration and retinal macroaneurysm. The best functional outcomes can be expected in patients regardless of the size and duration of the hemorrhage.

Intravitreal Injection of Recombinant Tissue Plasminogen Activator in Submacular Hemorrhage: Case Series

2016 ◽  
Vol 26 (3) ◽  
pp. e49-e51 ◽  
Author(s):  
Joana Araújo ◽  
Cristina Sousa ◽  
Pedro Alves Faria ◽  
Ângela Carneiro ◽  
Amândio Rocha-Sousa ◽  
...  
Keyword(s):  
Intravitreal Injection ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Case Series ◽  
Recombinant Tissue Plasminogen Activator ◽  
Submacular Hemorrhage ◽  
Tissue Plasminogen

Thrombolysis with recombinant tissue plasminogen activator during cardiopulmonary resuscitation in fulminant pulmonary embolism. A case series

Resuscitation ◽  
2001 ◽  
Vol 51 (1) ◽  
pp. 97-101 ◽  
Author(s):  
Manuel Ruiz-Bailén ◽  
Eduardo Aguayo-de-Hoyos ◽  
Marı́a del Carmen Serrano-Córcoles ◽  
Miguel Ángel Dı́az-Castellanos ◽  
Luis Javier Fierro-Rosón ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Cardiopulmonary Resuscitation ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Case Series ◽  
Recombinant Tissue Plasminogen Activator ◽  
Tissue Plasminogen

scholarly journals Outcomes of pars plana vitrectomy with subretinal tissue plasminogen activator injection and pneumatic displacement of fovea-involving submacular haemorrhage

2020 ◽  
Vol 5 (1) ◽  
pp. e000394 ◽  
Author(s):  
Carl S Wilkins ◽  
Neesurg Mehta ◽  
Chris Y Wu ◽  
Alexander Barash ◽  
Avnish A Deobhakta ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Pars Plana Vitrectomy ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Case Series ◽  
Subretinal Haemorrhage ◽  
Tissue Plasminogen ◽  
Pneumatic Displacement ◽  
Pars Plana

ObjectiveFovea-involving subretinal haemorrhage is challenging to manage with uncertain visual outcomes. We reviewed outcomes of patients with fovea-involving macular haemorrhage treated with pars plana vitrectomy (PPV) and subretinal tissue plasminogen activator (tPA) with pneumatic displacement.Methods and AnalysisThis is a retrospective interventional case series. All patients with submacular haemorrhage who underwent PPV with subretinal tPA injection were included. Reasons for exclusion encompassed patients who underwent intravitreal tPA injection in the office without surgery, insufficient follow-up or documentation. Primary outcomes of interest were postoperative visual acuity (VA) at month 1 and 3. Secondary outcomes were median VA at month 3 by location of haemorrhage and underlying diagnosis.ResultsThirty-seven total patients were included. The mean age was 68.2 years, with 54.1% (20/37) females. The most common aetiology was exudative macular degeneration (43.2%), followed by undifferentiated choroidal neovascularisation (CNV) (18.9%), polypoidal choroidal vasculopathy (18.9%), traumatic CNV (10.8%), macroaneurysm (5.4%) and proliferative diabetic retinopathy (2.7%). Median preoperative VA was 20/2000, postoperative month 1 was 20/347 (p<0.01), improving to 20/152 (p<0.01) at month 3. Proportion of patients gaining vision 3+ lines in vision was 15/36 (42%). Mean preoperative central subfield thickness on optical coherence tomography was 512.2 µm for sub-retinal pigment epithelium haemorrhage and 648.2 µm for subretinal haemorrhage (p=0.48). Difference in VA by diagnosis was not significant (p=0.60).ConclusionsPPV with subretinal tPA injection and pneumatic displacement of submacular haemorrhage offers modest visual recovery for a diverse group of patients. Location of haemorrhage or specific diagnosis may not predict outcome.

Sign in / Sign up

Export Citation Format

Share Document